Paper Details

  1. Home
  2. Paper Details

Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.

Author: ChenLuyi, ChenShujie, ChenXiaoli, ChenYujia, ChuHua, DengYanyong, GeQiwei, HeHuiqin, HeJiamin, LiAiqing, LongYanqin, WangLan

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A 14-day bismuth-furazolidone quadruple regimen is effective and safe for the initial eradication of Helicobacter pylori (H. pylori). In a study of 175 patients, the total eradication rate was 86.9% by intention-to-treat and 95.6% by per-protocol analysis. The efficacies of five different proton pump inhibitors (PPIs) showed no significant difference. Gastrointestinal symptoms and stool type improved significantly, while the total side effect rate and poor compliance rate were 15.7% and 5.0%, respectively.
Paper Details　
Original Abstract of the Article :
To evaluate potency and safety of 14-day bismuth-furazolidone quadruple regimens and to compare efficacies of five proton pump inhibitors (PPIs) for the initial eradication of Helicobacter pylori (H. pylori), 175 eligible patients were enrolled and randomly assigned to 14-day quadruple regimens cons...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10238-018-0510-9

データ提供：米国国立医学図書館（NLM）

Eradicating Helicobacter pylori: A Comparative Study of Bismuth-Furazolidone Quadruple Regimens

The battle against [Helicobacter pylori (H. pylori)] infection is an ongoing challenge in [gastroenterology]. This study compares the efficacy of five different [proton pump inhibitor (PPI)]-based [14-day bismuth-furazolidone quadruple regimens] for the initial eradication of H. pylori. Think of it as a grand culinary competition, where each PPI recipe vies for the title of most effective H. pylori eradication champion.

A Culinary Contest: Comparing the Efficacy of Different PPI Regimens

The researchers enrolled [175 patients] and randomly assigned them to different treatment groups, each featuring a different PPI. The study found that all five regimens demonstrated high [eradication rates] with [86.9% by ITT analysis] and [95.6% by PP analysis]. This suggests that these bismuth-furazolidone quadruple regimens are a potent weapon against H. pylori, regardless of the specific PPI used.

A Feast for the Stomach: The Safety and Tolerability of Quadruple Regimens

The study also found that these regimens were generally well-tolerated with a low rate of [adverse effects] and [poor compliance]. This is encouraging news, suggesting that patients can enjoy the benefits of these regimens with minimal discomfort. It's like a delicious meal that nourishes the body and fights infection, offering a much-needed respite from H. pylori.

Dr. Camel's Conclusion

This study, like a well-stocked desert caravan, offers a variety of options for eradicating H. pylori. The results highlight the effectiveness and safety of bismuth-furazolidone quadruple regimens, allowing clinicians to choose the most appropriate PPI for individual patients. This study serves as a valuable guide for clinicians seeking to combat H. pylori infection and improve patient outcomes.

Date :
  1. Date Completed 2019-07-01
  2. Date Revised 2021-03-09
Further Info :

Pubmed ID

29876770

DOI: Digital Object Identifier

10.1007/s10238-018-0510-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.